Symptom management in isocitrate dehydrogenase mutant glioma
- 19 October 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (Supplement) , i38-i48
Abstract
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality. With new treatments that improve progression-free and possibly overall survival, preventing and addressing daily symptoms becomes even more clinically relevant. In this review we discuss the management of the most prevalent symptoms, including tumor-related epilepsy, cognitive dysfunction, mood disorders, and fatigue, in patients with mIDH glioma, and issues regarding patient’s health-related quality of life and caregiver needs in the era of mIDH inhibitors. We provide recommendations for practicing healthcare professionals caring for patients who are eligible for treatment with mIDH inhibitors.Keywords
This publication has 140 references indexed in Scilit:
- Evaluation of the telehealth making sense of brain tumor psychological support intervention for people with primary brain tumor and their caregivers: A randomized controlled trialPsycho-Oncology, 2023
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- Treatment age and neurocognitive outcomes following proton beam radiotherapy for pediatric low‐ and intermediate‐grade gliomasPediatric Blood & Cancer, 2021
- Use of telehealth platforms for delivering supportive care to adults with primary brain tumors and their family caregivers: A systematic reviewPsycho-Oncology, 2020
- Understanding cognitive functioning in glioma patients: The relevance of IDH‐mutation status and functional connectivityBrain and Behavior, 2019
- Novel, improved grading system(s) for IDH-mutant astrocytic gliomasActa Neuropathologica, 2018
- Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational studyJournal of Neurology, 2017
- Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary reportCancer, 2016
- Epilepsy in low‐grade gliomas: The impact on cognitive function and quality of lifeAnnals of Neurology, 2003
- Cognitive functions and quality of life in patients with low‐grade gliomas: The impact of radiotherapyAnnals of Neurology, 1994